Clinical trials: Lung Cancer Small Cell Lung Cancer (SCLC)
Non-Small Cell Lung Cancer
Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors
The aim of the COMBINATION trial is to prospectively study the sequential approach of using afatinib combined with a short course of chemotherapy, followed by osimertinib, upon progression and acquisition of a T790M mutation…
- Trial name
- COMBINATION (NCT05298176)
- Testing
- Afatinib, Osimertinib, Carboplatin and Pemetrexed
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Amsterdam UMC, location VUmc
Lung Cancer
Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer
RATIONALE: Determining whether erlotinib passes into the cerebrospinal fluid may help in planning treatment for some types of cancer.
- Trial name
- NCT00305617
- Testing
- antitumor drug screening assay
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Cleveland Clinic
Non-Small Cell Lung Cancer
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
The primary objective of Part I of the study is to determine tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide /carboplatin in chemotherapy-naïve patients with extensive…
- Trial name
- NCT00240097
- Testing
- Intervention A: Irinotecan; Oxaliplatin; Neulasta, Intervention B: Etoposide; Carboplatin; Neulasta
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Extensive Stage Small Cell Lung Cancer
The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer
This trial will investigate the addition of an antibody (Ipilimumab) to conventional Carboplatin and Etoposide chemotherapy in extensive stage small cell lung cancer.
- Trial name
- ICE (NCT01331525)
- Testing
- Ipilimumab
- Where
- 7 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Small Cell Lung Cancer
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.
- Trial name
- NCT00374140
- Testing
- RAD001 (everolimus)
- Where
- 19 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ahmad Tarhini
Non-small Cell Lung Cancer Stage III
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint…
- Trial name
- NCT06031597
- Testing
- radiotherapy, Platinum-Based Drug, Immunotherapy
- Volunteers
- 105 people
- Sponsor
- Zhejiang Cancer Hospital
Small Cell Lung Carcinoma, Neuroendocrine Neoplasms
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists.
- Conditions
- Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
- Trial name
- NCT05882058
- Testing
- BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Medical Oncology
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial…
- Trial name
- NCT02639091
- Testing
- BAY 94-9343, Pemetrexed, Cisplatin
- Where
- 6 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Bayer
Non-small Cell Lung Cancer
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
The primary objective is to evaluate the intracranial efficacy of pemetrexed/carboplatin chemotherapy and lazertinib combination therapy after osimertinib failure in EGFR-positive non-small cell lung cancer patients with brain…
- Trial name
- NCT05477615
- Testing
- Lazertinib, Pemetrexed, Carboplatin
- Where
- 6 sites in South Korea
- Volunteers
- 14 people
- Sponsor
- Jin Hyoung Kang
Lung Cancer, Metastatic Cancer
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00738335
- Testing
- erlotinib hydrochloride, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Sponsor
- University of California, San Francisco
Stage II-III Non-small Cell Lung Cancer
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
This is a randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) combined with platinum-based doublet drug chemotherapy versus…
- Trial name
- NCT04158440
- Testing
- 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
- Where
- China
- Volunteers
- 501 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Non-Small-Cell Lung Carcinoma
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
This is a Japan Extension Study of Global Study MK-3475-189 (NCT02578680). This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy…
- Trial name
- NCT03950674
- Testing
- Pembrolizumab 200 mg, Cisplatin, Carboplatin
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination…
- Trial name
- NCT00193323
- Testing
- Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- SCRI Development Innovations, LLC
Non-Small Cell Lung Cancer, EGFR Mutation
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
Protocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer The main purpose of this research study is to Find a safe…
- Conditions
- Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
- Trial name
- NCT07285148
- Testing
- ANS014004 + PLB1004, ANS014004 + Osimertinib
- Where
- United States
- Volunteers
- 253 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Non-squamous Non-small-cell Lung Cancer
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small…
- Trial name
- NCT05318443
- Testing
- SIBP04, Avastin, Paclitaxel
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Shanghai Institute Of Biological Products
NSCLC
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels >30 pg/ml.
- Trial name
- NCT00576225
- Testing
- CT-2103/carboplatin, paclitaxel/carboplatin
- Where
- 44 sites in United States
- Sponsor
- CTI BioPharma
Carcinoma, Non-Small-Cell Lung
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen
- Trial name
- SUN1058 (NCT00265317)
- Testing
- erlotinib, sunitinib
- Where
- 32 sites in United States, Canada and 6 more
- Volunteers
- 162 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer
This study is intended to evaluate the role of paclitaxel poliglumex and carboplatin in the treatment of unresectable Stage III non-small cell lung cancer along with radiation therapy in a multi-institutional trial.
- Trial name
- NCT00352690
- Testing
- Paclitaxel poliglumex, Carboplatin, External beam radiation therapy
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Non-Small Cell Lung Cancer, Lung Function
Vibration Response Imaging (VRI) in the Preoperative Management in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to assess the correlation of the predicted post-operative lung function with the observed post-operative lung function (FEV1 and DLCO) in patients who underwent surgical resection (FEV1 = Forced…
- Trial name
- NCT00845143
- Volunteers
- 100 people
- Sponsor
- Heidelberg University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.